MXPA04000028A - Pharmaceutical formulation for the intramuscular administration of fulvestrant. - Google Patents

Pharmaceutical formulation for the intramuscular administration of fulvestrant.

Info

Publication number
MXPA04000028A
MXPA04000028A MXPA04000028A MXPA04000028A MXPA04000028A MX PA04000028 A MXPA04000028 A MX PA04000028A MX PA04000028 A MXPA04000028 A MX PA04000028A MX PA04000028 A MXPA04000028 A MX PA04000028A MX PA04000028 A MXPA04000028 A MX PA04000028A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
fulvestrant
intramuscular administration
administration
ricinoleate vehicle
Prior art date
Application number
MXPA04000028A
Other languages
Spanish (es)
Inventor
Kay Cahill Julie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA04000028A publication Critical patent/MXPA04000028A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention relates to a sustained release pharmaceutical formulation adapted for administration by injection containing the compound fulvestrant, 7 a-[9 -(4, 4, 5, 5, 5 -pentafluoropentylsulphiny1) nony1] oestra-1, 3, 5(10)-triene -3, 17 ss-diol, at concentration of at least 100mg/ml in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
MXPA04000028A 2001-07-07 2004-01-07 Pharmaceutical formulation for the intramuscular administration of fulvestrant. MXPA04000028A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30

Publications (1)

Publication Number Publication Date
MXPA04000028A true MXPA04000028A (en) 2004-05-21

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000028A MXPA04000028A (en) 2001-07-07 2004-01-07 Pharmaceutical formulation for the intramuscular administration of fulvestrant.

Country Status (15)

Country Link
EP (1) EP1406662A1 (en)
JP (1) JP2004534093A (en)
CN (1) CN1553815A (en)
AR (1) AR037138A1 (en)
BR (1) BR0210898A (en)
CA (1) CA2453111A1 (en)
CO (1) CO5560585A2 (en)
HU (1) HUP0400115A3 (en)
IL (1) IL159576A0 (en)
IS (1) IS7097A (en)
MX (1) MXPA04000028A (en)
NO (1) NO20040047L (en)
PL (1) PL367624A1 (en)
RU (1) RU2004102393A (en)
WO (1) WO2003006064A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US8586092B2 (en) 2009-08-31 2013-11-19 Xi'an Libang Pharmaceutical Technology Co., Ltd. Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600065B (en) * 2012-03-31 2014-08-13 莱普德制药有限公司 Fulvestrant or fulvestrant derivative oily preparation and preparation method thereof
CN102600064A (en) * 2012-03-31 2012-07-25 西安力邦制药有限公司 Fulvestrant or fulvestrant derivative sustained release preparation and preparation method thereof
CN102600073B (en) * 2012-03-31 2014-01-01 莱普德制药有限公司 Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method of oily preparation
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
CN108883118B (en) * 2016-04-06 2021-06-15 富士胶片株式会社 Pharmaceutical composition
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
JP2019516789A (en) * 2016-05-06 2019-06-20 イーグル ファーマスーティカルズ、インク． Fulvestrant formulation and method of use thereof
EP3466430B1 (en) 2016-05-31 2020-04-29 FUJIFILM Corporation Pharmaceutical composition
JP7220712B2 (en) * 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． Fulvestrant Formulations and How to Use Them
WO2019113361A1 (en) * 2017-12-07 2019-06-13 Nevakar Inc. Concentrated fulvestrant compositions
WO2019151353A1 (en) * 2018-01-31 2019-08-08 富士フイルム株式会社 Method for producing preparation for injection
CN111481559B (en) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 High-concentration fulvestrant composition and preparation method thereof
CN113260353A (en) * 2019-12-11 2021-08-13 上海博志研新药物技术有限公司 Fulvestrant pharmaceutical composition, preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
JP2004534093A (en) 2004-11-11
CN1553815A (en) 2004-12-08
WO2003006064A1 (en) 2003-01-23
IS7097A (en) 2004-01-05
HUP0400115A3 (en) 2005-11-28
EP1406662A1 (en) 2004-04-14
BR0210898A (en) 2004-06-22
HUP0400115A2 (en) 2004-06-28
PL367624A1 (en) 2005-03-07
IL159576A0 (en) 2004-06-01
CO5560585A2 (en) 2005-09-30
CA2453111A1 (en) 2003-01-23
AR037138A1 (en) 2004-10-27
NO20040047L (en) 2004-02-23
RU2004102393A (en) 2005-03-27

Similar Documents

Publication Publication Date Title
ES2186517A1 (en) Fulvestrant formulation
MXPA04000028A (en) Pharmaceutical formulation for the intramuscular administration of fulvestrant.
WO2002100344A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
CY1107142T1 (en) STANDARDIZATION INCLUDING FULVESTRANT
WO2006052921A3 (en) Cyclodextrin solubilizers for liquid and semi-solid formulations
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
PT1123120E (en) MEDICINAL FORMULATION IN AEROSOL
EP1938821A3 (en) Methods of administering epothilone analogs for the treatment of cancer
ATE225174T1 (en) SELF-EMULSIFYING FORMULATION CONTAINING ACIDIC LIPOPHILIC COMPOUNDS
WO2002032376A3 (en) Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2001260455A1 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2002042414A3 (en) Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2001261516A1 (en) Semi-solid delivery vehicle and pharmaceutical compositions
GT199800196A (en) COMBINATIONS OF STATIN-CARBOXYALKYL ETHER.
BR0312004A (en) Transdermal Aerosol Compositions
AR018888A1 (en) A TESTOSTERONE DERIVATIVE, USE OF THE SAME, A PHARMACEUTICAL FORMULATION THAT INCLUDES THE DERIVATIVE AND A KIT FOR MALE ANTI-CONCEPTION
HK1052946A1 (en) Dry compositions containing hydrophobic amino acid
DE60017720D1 (en) PHARMACEUTICAL EMULSIONS FOR RETROVIRAL-PROTEASE-INHIBITING COMPOUNDS
ES2141049A1 (en) Aerosol pharmaceutical formulations which contain medium- chain triglycerides as surfactants.